Anoop K. Enjeti
Lookout Road
New Lambton, NSW 2305, Australia
New Lambton, NSW 2305, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 76 publications
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).
Journal: American journal of hematology
Published: June 25, 2026
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.
Journal: Blood cancer journal
Published: March 13, 2026
Infection risk in myelodysplastic syndromes is dynamic and immune driven.
Journal: Blood advances
Published: January 27, 2026
Beyond initial response: Acquired resistance to hypomethylating agents in myeloid malignancies.
Journal: Critical reviews in oncology/hematology
Published: December 11, 2025
Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for acute myeloid leukemia cell self-renewal.
Journal: Leukemia
Published: February 10, 2025
Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs.
Journal: Nature communications
Published: September 26, 2024
Next-generation karyotyping using optical genome mapping: a comparative study of genomic changes in haematological malignancies.
Journal: Pathology
Published: August 26, 2024
Combination therapy in cancer: The potential of tetrandrine as a polytherapy for acute myeloid leukemia.
Journal: Biochimica et biophysica acta. Reviews on cancer
Published: July 17, 2024
Last Updated: 09/26/2026